Synthesis of metabolites of dapagliflozin: an SGLT2 inhibitor

被引：0
|
作者：
KISHORE KARUMANCHI
SENTHIL KUMAR NATARAJAN
RAMADAS CHAVAKULA
RAGHU BABU KORUPOLU
KISHORE BABU BONIGE
BADARINADH GUPTA PERURI
机构：
[1] Aurobindo Pharma Ltd.,Chemical Research and Development, APL Research Centre
[2] Andhra University,II
[3] Aurobindo Pharma Ltd,Department of Engineering Chemistry, A. U. College of Engineering (A)
来源：
Journal of Chemical Sciences | 2020年 / 132卷
关键词：
Dapagliflozin; SGLT2 inhibitor; Anti diabetic drug; Metabolites; Synthesis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Synthesis of metabolites of dapagliflozin: an SGLT2 inhibitor
    Karumanchi, Kishore
    Natarajan, Senthil Kumar
    Chavakula, Ramadas
    Korupolu, Raghu Babu
    Bonige, Kishore Babu
    Peruri, Badarinadh Gupta
    [J]. JOURNAL OF CHEMICAL SCIENCES, 2020, 132 (01)
  • [2] Synthesis of metabolites of dapagliflozin: an SGLT2 inhibitor
    Karumanchi, Kishore
    Natarajan, Senthil Kumar
    Chavakula, Ramadas
    Korupolu, Raghu Babu
    Bonige, Kishore Babu
    Peruri, Badarinadh Gupta
    [J]. Journal of Chemical Sciences, 2020, 132 (01):
  • [3] Dapagliflozin, an SGLT2 inhibitor, for diabetes
    Hanefeld, Markolf
    Forst, Thomas
    [J]. LANCET, 2010, 375 (9733): : 2196 - 2198
  • [4] Hyperkalemia Incidence with the SGLT2 Inhibitor Dapagliflozin
    Yavin, Yshai
    Mansfield, Traci A.
    Ptaszynska, Agata
    Apanovitch, Anne Marie
    Johnsson, Kristina M.
    Johnsson, Eva
    Parikh, Shamik J.
    List, James F.
    [J]. DIABETES, 2014, 63 : A282 - A282
  • [5] Omic effects of SGLT2 inhibitor dapagliflozin
    Billing, A.
    Kim, Y. -C.
    Fenton, R.
    Vallon, V.
    Rinschen, M.
    [J]. ACTA PHYSIOLOGICA, 2022, 236 : 299 - 299
  • [6] Dapagliflozin. SGLT2 inhibitor, Antidiabetic agent
    Cole, P.
    Vicente, M.
    Castaner, R.
    [J]. DRUGS OF THE FUTURE, 2008, 33 (09) : 745 - 751
  • [7] DAPAGLIFLOZIN, AN SGLT2 INHIBITOR FOR THE TREATMENT OF TYPE 2 DIABETES
    Demaris, K. M.
    White, J. R.
    [J]. DRUGS OF TODAY, 2013, 49 (05) : 289 - 301
  • [8] Systemic proteomic and metabolomic signature of the SGLT2 inhibitor dapagliflozin
    Billing, Anja
    Kim, Young-Chul
    Vallon, Volker
    Rinschen, Markus
    [J]. FASEB JOURNAL, 2022, 36
  • [9] Dapagliflozin, Selective SGLT2 Inhibitor, Does Not Increase Risk of Fractures
    Ptaszynska, Agata
    Mansfield, Traci
    Apanovitch, Anne Marie
    Johnsson, Kristina M.
    Johnsson, Eva
    Parikh, Shamik J.
    List, James F.
    [J]. DIABETES, 2014, 63 : A282 - A282
  • [10] SGLT2 inhibitor dapagliflozin promotes glucagon secretion in α islet cells
    Jennifer Sargent
    [J]. Nature Reviews Endocrinology, 2015, 11 (7) : 382 - 382
12345